Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing

BACKGROUND: Atypia of undetermined significance (AUS; Bethesda category III) is a heterogeneous thyroid fine-needle aspiration (FNA) category with variable malignancy risk. Molecular testing guides AUS management in North America but is unavailable or cost-prohibitive in much of the world. This study evaluated repeat FNA as primary AUS triage and the contribution of cytomorphologic subclassification in a population-based cohort without molecular testing. METHODS: The authors identified all AUS thyroid FNAs in the Fraser Health Authority, British Columbia (2014-2019), with follow-up through 2022. Index cytology was subclassified by architectural, morphologic/nuclear, and oncocytic atypia. Repeat-FNA outcomes, surgical pathology, and clinical/radiologic data were correlated; noninvasive follicular thyroid neoplasm with papillary-like nuclear features was classified as nonmalignant. RESULTS: Among 611 AUS nodules, 271 (44.4%) underwent repeat FNA and 237 (38.8%) resection. Resection-based risk of malignancy (ROM) was 32.9% (78 of 237); minimum observed malignancy was 12.8% (78 of 611). The second FNA was benign in 116 (42.8%), persistent AUS in 78 (28.8%), nondiagnostic in 58 (21.4%), and upgraded in 19 (7.0%). Minimum observed malignancy was 2.6% (3 of 116) after a benign versus 47.4% (9 of 19) after an upgraded second FNA. A benign repeat FNA obviated surgery in 103 of 116 (88.8%). AUS-nuclear carried a higher ROM than AUS-other (38.6% vs. 21.5%; p = .008; adjusted odds ratio, 2.33; 95% CI, 1.24-4.38) but did not predict repeat-FNA outcome (p = .420). CONCLUSIONS: In a molecular-testing-free, population-based cohort, repeat FNA effectively triaged AUS: benign resolution was frequent and marked very low malignancy risk, whereas persistent or upgraded cytology selected nodules for surgery. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as cost-effective first-line management where molecular testing is unavailable.

Authors

Institutions

Publication Details

Journal
Cancer Cytopathology
Published
2026-11-18
DOI
https://doi.org/10.1002/cncy.70171
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing

Reza Alaghehbandan, Neha Khaitan, Christopher C Griffith, Lara Maria Stričak et al.
1 links
Cancer Cytopathology
Thyroid Cancer Diagnosis and Treatment
article

Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing

Reza Alaghehbandan, Neha Khaitan, Christopher C Griffith, Lara Maria Stričak, Khashayar Saybani, Paria Sokhanran, Karolina Oscilowicz, Ghazal Sokhanran, Anita Zamanigohar, Aland Barzinjy, Jaleh Esmaeeli, Yung‐Fang Tu
article en

Abstract

BACKGROUND: Atypia of undetermined significance (AUS; Bethesda category III) is a heterogeneous thyroid fine-needle aspiration (FNA) category with variable malignancy risk. Molecular testing guides AUS management in North America but is unavailable or cost-prohibitive in much of the world. This study evaluated repeat FNA as primary AUS triage and the contribution of cytomorphologic subclassification in a population-based cohort without molecular testing. METHODS: The authors identified all AUS thyroid FNAs in the Fraser Health Authority, British Columbia (2014-2019), with follow-up through 2022. Index cytology was subclassified by architectural, morphologic/nuclear, and oncocytic atypia. Repeat-FNA outcomes, surgical pathology, and clinical/radiologic data were correlated; noninvasive follicular thyroid neoplasm with papillary-like nuclear features was classified as nonmalignant. RESULTS: Among 611 AUS nodules, 271 (44.4%) underwent repeat FNA and 237 (38.8%) resection. Resection-based risk of malignancy (ROM) was 32.9% (78 of 237); minimum observed malignancy was 12.8% (78 of 611). The second FNA was benign in 116 (42.8%), persistent AUS in 78 (28.8%), nondiagnostic in 58 (21.4%), and upgraded in 19 (7.0%). Minimum observed malignancy was 2.6% (3 of 116) after a benign versus 47.4% (9 of 19) after an upgraded second FNA. A benign repeat FNA obviated surgery in 103 of 116 (88.8%). AUS-nuclear carried a higher ROM than AUS-other (38.6% vs. 21.5%; p = .008; adjusted odds ratio, 2.33; 95% CI, 1.24-4.38) but did not predict repeat-FNA outcome (p = .420). CONCLUSIONS: In a molecular-testing-free, population-based cohort, repeat FNA effectively triaged AUS: benign resolution was frequent and marked very low malignancy risk, whereas persistent or upgraded cytology selected nodules for surgery. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as cost-effective first-line management where molecular testing is unavailable.

Cancer CytopathologyVol. 134(12)
Cleveland Clinic (US), Royal Columbian Hospital (CA), University of British Columbia (CA), Henry Ford Health System (US), Simon Fraser University (CA), University of Zagreb (HR), New Cross Hospital (GB), Henry Ford Hospital (US), Wojewódzki Szpital Specjalistyczny we Wrocławiu (PL), The Royal Wolverhampton NHS Trust (GB)
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon